EGFR and neoplasm: Another targeted approach that could be employed for GB tumors is the one designed by Ohno et al. [212], which uses exosomes modified with the GE11 peptide (an EGFR ligand) and carrying the tumor suppressor let-7 for targeting EGFR-positive breast cancer cells and reducing tumor growth in vivo.